LABATEC PHARMA ANNOUNCES AN EXCLUSIVE LICENSING AGREEMENT SIGNED WITH AFT PHARMACEUTICALS, TO COMMERCIALISE MAXIGESIC IV®, IN SWITZERLAND
Geneva, March 27, 2023 – Labatec Pharma SA (Labatec) signed a new licensing agreement with AFT Pharmaceuticals (NZX.AFT, ASX.AFP), for the exclusive rights to commercialise Maxigesic IV® in Switzerland, a treatment for mild to moderate pain for use post-operatively in hospitals when patients cannot take a medicine orally.
In the terms of the agreement, Labatec will take care of all commercial activities related to Maxigesic IV® including sales, marketing, medical affairs, pricing, and reimbursement while AFT will be responsible for supplying the drug to Labatec.
Faisal Darwazeh, CEO of Labatec “We are broadening our hospital portfolio with this novel essential medicine for our patients in Switzerland. Maxigesic IV® will strengthen our innovative medicine portfolio, enhancing Labatec’s established role as a trusted partner to Swiss hospitals.”
Both companies are aiming for registration and launch of this innovative intravenous pain relief medicine in the next 12 to 18 months in Switzerland.
For further information please contact:
Labatec Pharma SA
Business Development Team
Email: partnering@labatec.com
Tel: +41 22 785 95 00 (Head Office)
For media enquiries please contact:
Labatec Pharma SA
Head of Press & Communications
Email: press@labatec.com
Tel: +41 22 785 95 00 (Head Office)
About Labatec
A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva). Labatec develops and markets medicines that contribute to improving patients’ quality of life. Labatec is a leading licensing partner in the specialty and innovative medicines segments, across the Swiss and MENA markets.
Labatec’s extensive portfolio includes more than 100 high-quality products, manufactured in Europe and Canada, and supplied to 14 countries comprising Switzerland, Austria, the Middle East and North Africa. Labatec is a recognized partner of choice for hospitals (anti-infectious, anesthetic, antiemetic and oncological products) and has an established retail presence in the therapeutic categories of osteoporosis, muscle relaxants, women’s health and ophthalmology. For more information about the company, visit our website https://www.labatecpharma.com/
About AFT Pharmaceuticals
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter (OTC), prescription and hospital. AFT is present in Australia, New Zealand and in certain Southeast Asian markets, and through local partners in over 125 countries. www.aftpharm.com
29 March 2023
david
News
« March 4th is International Human Papillomavirus Awareness Day!
LABATEC PHARMA ANNOUNCES EXCLUSIVE LICENSING AGREEMENT
SIGNED WITH RADIUS HEALTH INC, TO COMMERCIALISE TYMLOS
IN SWITZERLAND AND THE MIDDLE EAST NORTH AFRICA REGION
Geneva, June 9, 2022 – Labatec Pharma SA (Labatec) signed a new licensing agreement with Radius Health, Inc. (Radius) (NASDAQ: RDUS), for the rights to commercialise TYMLOS® (abaloparatide), a subcutaneous injection for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
In accordance with the terms of the agreement, Labatec will register, commercialize, and distribute TYMLOS on an exclusive basis in Switzerland and the Middle East North Africa (MENA) region including Bahrain, Iraq, Jordan, Kuwait, Oman, Qatar, Saudi Arabia, UAE, Algeria, and Morocco. The responsibilities include all commercial activities related to TYMLOS including sales, marketing, medical affairs, pricing, and reimbursement. Radius will be responsible for supplying the drug to Labatec.
Faisal Darwazeh, CEO of Labatec: “We are pleased to enter in a partnership with Radius, to bring an alternative and innovative treatment for osteoporosis to our patients in Switzerland and the MENA region, building on our existing and growing portfolio of licensed and innovative medicines. We are looking forward to this collaboration.”
Chhaya Shah, Senior Vice President of Radius (leader of the clinical and regulatory activity for abaloparatide): “We are delighted to partner with Labatec in these very important countries and to make TYMLOS available to patients who suffer from osteoporosis.”
About Labatec
A Swiss based privately owned pharmaceutical company, based in Meyrin (Geneva). Labatec develops and markets medicines that contribute to improving patients’ quality of life. Labatec is a leading licensing partner in the specialty and innovative medicines segments, across the Swiss and MENA markets.
Labatec’s extensive portfolio includes more than 70 high-quality products, manufactured in Europe and Canada, and supplied to 14 countries comprising Switzerland, Austria, the Middle East and North Africa. Labatec is a recognized partner of choice for hospitals (anti-infectious, anesthetic, antiemetic and oncological products) and has an established retail presence in the therapeutic categories of osteoporosis, muscle relaxants, women’s health and opthamology.
http://www.labatecpharma.com/
For further information please contact:
Labatec Pharma SA
Business Development Team
Email: bd@labatec.com
Tel: +41 22 785 95 00 (Head Office)
For media enquiries please contact:
Labatec Pharma SA
Head of Press & Communications
Email: press@labatec.com
Tel: +41 22 785 95 00 (Head Office)
About Radius
Radius is a global biopharmaceutical company focused on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. Radius’ lead product, TYMLOS® (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; the investigational drug, elacestrant (RAD1901), for potential use in the treatment of hormone-receptor positive breast cancer out-licensed to Menarini Group; and the investigational drug RAD011, a synthetic cannabidiol oral solution with potential utilization in multiple neuro-endocrine, neurodevelopmental, or neuropsychiatric disease areas, initially targeting Prader-Willi syndrome, Angelman syndrome, and infantile spasms.
TYMLOS (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture defined as history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapies.
For further information please contact:
Investor & Media Relations
Ethan Holdaway
Email: investor-relations@radiuspharm.com
Phone: (617) 583-2017
14 June 2022
david
News
March 4th is International Human Papillomavirus Awareness Day! »
